Eisai

Arena, Orexigen Race for a Fat Opportunity
Arena, Orexigen Race for a Fat Opportunity
Seeking Alpha
obesity
Arena Pharmaceuticals
Orexigen
Contrave
Eisai
Flag link:
Will Prescription Diet Pills Become Hot - Again?
Will Prescription Diet Pills Become Hot - Again?
Pharmalot
diet drugs
obesity
Arena Pharmaceuticals
Eisai
Contrave
Orexigen
Flag link:
Eisai Will Sell Arena's Hunger-Curbing Obesity Pill in the U.S. If Cleared
Eisai Will Sell Arena's Hunger-Curbing Obesity Pill in the U.S. If Cleared
Bloomberg
obesity
Eisai
Arena Pharmaceuticals
Flag link:
FDA Warns Drug Makers On Misleading Promotional Efforts
FDA Warns Drug Makers On Misleading Promotional Efforts
NASDAQ.com
FDA
warnings
Cumberland
Auxilium
Dainippon Sumitomo
Eisai
Flag link:
Phase III Study Results Showed Eisai’s Eribulin Mesylate Significantly Improved Overall Survival in Patients with Locally Recurrent or Metastatic Breast Cancer
Phase III Study Results Showed Eisai’s Eribulin Mesylate Significantly Improved Overall Survival in Patients with Locally Recurrent or Metastatic Breast Cancer
BusinessWire
Eisai
Eribulin Mesylate
breast cancer
Flag link:
Eisai’s Breast Cancer Drug Gets Priority Review
Eisai’s Breast Cancer Drug Gets Priority Review
Bloomberg
Eisai
FDA
breast cancer
Eribulin
Flag link:
Is Secrecy Hurting Drug Research?
Is Secrecy Hurting Drug Research?
Forbes
R&D
AstraZeneca
Roche
GSK
Eisai
ONYX Pharmaceuticals
Flag link:
Eisai Cuts Aricept Price, Joining Glaxo, Sanofi Race in Asia
Eisai Cuts Aricept Price, Joining Glaxo, Sanofi Race in Asia
Bloomberg
Eisai
Aricept
GSK
Asia
Sanofi
Flag link:
Eisai Seeks Approval for Breast Cancer Drug Globally
Eisai Seeks Approval for Breast Cancer Drug Globally
Bloomberg
Eisai
breast cancer
Eribulin
Flag link:
Eisai Revenues Set to Fall Off the 'Patent Cliff' as Sepsis Drug Hits Delay
Eisai Revenues Set to Fall Off the 'Patent Cliff' as Sepsis Drug Hits Delay
Seeking Alpha
Eisai
Aricept
eritoran
Flag link:
Industry News Bytes: Delcath, Amylin and Access Pharma
Industry News Bytes: Delcath, Amylin and Access Pharma
Seeking Alpha
Delcath
Access Pharmaceuticals
Amylin
Eli Lilly
Alkermes
Eisai
Flag link:
Eisai says FDA approved new Dacogen dosing
Eisai says FDA approved new Dacogen dosing
Yahoo/AP
FDA
Eisai
Dacogen
Flag link:
Eisai says Aricept's U.S. sales to more than halve
Eisai says Aricept's U.S. sales to more than halve
Reuters
Eisai
Aricept
Flag link:
Partnering Activity Skyrockets as Biotechs Close Year-End Deals
Partnering Activity Skyrockets as Biotechs Close Year-End Deals
BNET Pharma
biotech
* Incyte
Eli Lilly
OncoGenex
Teva Pharmaceuticals
Biovitrum
Eisai
AkaRx
Thallion Pharmaceuticals
LFB Biotechnologies
Athersys
Pfizer
Myriad
Javelin
Durata Therapeutics
Vicuron
Flag link:
Japan's Eisai to buy US drug firm AkaRx for $255 mln
Japan's Eisai to buy US drug firm AkaRx for $255 mln
Reuters
AkaRx
M&A
Eisai
Flag link:
Global Phase III Study Results Show Eribulin Meets Primary Endpoint of Overall Survival
Global Phase III Study Results Show Eribulin Meets Primary Endpoint of Overall Survival
PR NewsWire
Eisai
Eribulin
breast cancer
Flag link:
Pfizer and Eisai Continue Aricept Collaboration
Pfizer and Eisai Continue Aricept Collaboration
Yahoo
Pfizer
Eisai
Aricept
Flag link:
Morphotek(R), Inc. and Cancer Innovations, Inc. Announce Evaluation and Option Agreement for Therapeutic Monoclonal Antibodies
Morphotek(R), Inc. and Cancer Innovations, Inc. Announce Evaluation and Option Agreement for Therapeutic Monoclonal Antibodies
PR NewsWire
Morphotec
Cancer Innovations
Eisai
Flag link:
Eisai’s Aricept, Alzheimer’s Rivals Fail to Get Wider U.K. Use
Eisai’s Aricept, Alzheimer’s Rivals Fail to Get Wider U.K. Use
Bloomberg
Eisai
Aricept
Alzheimer's disease
UK
Flag link:
Eisai Is Confident of Aricept Sales Without Pfizer
Eisai Is Confident of Aricept Sales Without Pfizer
Bloomberg
Aricept
Pfizer
Eisai
Alzheimer's disease
Flag link:

Pages